While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
TipRanks on MSN
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt
InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...
Leg ulcers form when skin on your leg breaks open. These breaks or sores let air and bacteria travel into your skin’s tissue. For most people, leg ulcers will heal on their own and won’t need medical ...
(RTTNews) - InflaRx N.V. (IFRX) today released detailed analyses from its terminated Phase 3 trial of Vilobelimab in pyoderma gangrenosum. The study was stopped in May 2025 after an Independent Data ...
People who have an inflammatory bowel disease like ulcerative colitis often have problems caused by inflammation in other parts of their bodies. One of these is a skin condition called pyoderma ...
Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...
A 59-year-old woman with systemic lupus erythematosus presented with a 1-month history of an enlarging, exquisitely painful ulcer on her left calf (Figure 1). She reported that it had occurred ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results